Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Chinese Researchers Developing Anti-bacterial Ruthenium PSs
View:
Post by Eoganacht on Aug 02, 2022 11:55am

Chinese Researchers Developing Anti-bacterial Ruthenium PSs

For what it's worth, Theralase demonstrated photodynamic inactivation of Staphylococcus aureus using TLD1411 and TLD1433 and green light (530 nm) back in 2013.

Photodynamic inactivation of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus with Ru(II)-based type I/type II photosensitizers

Yaxal Arenas, Susan Monro, Ge Shi, Arkady Mandel, Sherri McFarland, Lothar Lilge

The Chinese researchers are developing new anti-bacterial ruthenium compounds that are activated by long wavelengths (808 nm) 

Long wavelength–emissive Ru(II) metallacycle–based photosensitizer assisting in vivo bacterial diagnosis and antibacterial treatment

Yuling Xu, Chonglu Li, Xin Ma, Wei Tuo, Le Tu, Xiaopeng Li, Yan Sun, Peter J. Stang, and Yao Sun
 
August 1, 2022
 
Significance
 
Bacterial infection is the major risk to public health. Developing emissive metal–based photosensitizers against bacterial infections draws continued interest in biomedicine. The most important issue is extending the absorption and emission wavelengths of metal-based photosensitizers to ameliorate the efficiency of in vivo imaging and phototherapy. To address this, we rationally designed a long-wavelength–emissive ruthenium (II) metallacycle (herein referred to as 1) that has superior optical penetration (∼7 mm) and satisfactory reactive oxygen species–generation performance. Complex 1 has promising broad-spectrum antibacterial activity and low toxicity to mammalian cells. Moreover, 1 enables high-performance, in vivo, fluorescent imaging-guided phototherapy of Staphylococcus aureus–infected mice, with ignorable adverse effects, thus demonstrating that 1 could be a good platform for pathogen phototheranostics.
 
Abstract
 
Ruthenium (Ru) complexes are developed as latent emissive photosensitizers for cancer and pathogen photodiagnosis and therapy. Nevertheless, most existing Ru complexes are limited as photosensitizers in terms of short excitation and emission wavelengths. Herein, we present an emissive Ru(II) metallacycle (herein referred to as 1) that is excited by 808-nm laser and emits at a wavelength of ∼1,000 nm via coordination-driven self-assembly. Metallacycle 1 exhibits good optical penetration (∼7 mm) and satisfactory reactive oxygen species production properties. Furthermore, 1 shows broad-spectrum antibacterial activity (including against drug-resistant Escherichia coli) as well as low cytotoxicity to normal mammalian cells. In vivo studies reveal that 1 is employed in precise, second near-infrared biomedical window fluorescent imaging–guided, photo-triggered treatments in Staphylococcus aureus–infected mice models, with negligible side effects. This work thus broads the applications of supramolecular photosensitizers through the strategy of lengthening their wavelengths.
Comment by hilles on Aug 02, 2022 12:17pm
Are they stealing our technology? Hilles
Comment by skier59 on Aug 02, 2022 12:24pm
That's what they have been known to do !
Comment by Rumpl3StiltSkin on Aug 02, 2022 12:48pm
It seems to me that TLT has always put their antibiotic solution on the back burner to focus on Cancer. That is fine. Someday some big pharma will have control over this tech and be able to compete with whatever new antibiotic tech is out there. Things need to change so we get away from using the old antibiotics, before we create a superbug... If China gets there first that is ok. It needs to ...more  
Comment by gordo323 on Aug 02, 2022 12:55pm
Level II   Theralase Technologies Inc. (CA:TLT) Size Bid Ask Size 2500 0.345 0.360 12500 18000 0.335 0.365 29500 3000 0.330 0.370 48000 3000 0 ...more  
Comment by ScienceFirst on Aug 02, 2022 2:21pm
Scientists share research through conferences.  That's how trends are known to others.    
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250